Transgenic mice expressing proteins altering polyamine levels in a tissue-specific manner have considerable promise for evaluation of the roles of polyamines in normal, hypertrophic and neoplastic growth. This short review summarizes the available transgenic models. Mice with large increases in ornithine decarboxylase (ODC), S-adenosylmethionine decarboxylase or antizyme, a protein regulating polyamine synthesis by reducing polyamine transport and ODC in the heart, have been produced using constructs in which the protein is expressed from the α-myosin heavy-chain promoter. These mice are useful in studies of the role of polyamines in hypertrophic growth. Expression from keratin promoters has been used to target increased synthesis of ODC, spermidine/spermine-N 1 -acetyltransferase (SSAT) and antizyme in the skin.
donor, decarboxylated S-adenosylmethionine, is formed from S-adenosylmethionine by S-adenosylmethionine decarboxylase (AdoMetDC). The sequential synthesis of spermidine and spermine is then accomplished by two aminopropyltransferase enzymes, spermidine synthase and spermine synthase. These aminopropyltransferase reactions are essentially irreversible, but reversal of the pathway can occur via the activity of FAD-dependent polyamine oxidases (PAOs) that remove the aminopropyl groups [6] . The first such oxidase to be cloned, PAO1 (also called spermine oxidase, SMO), acts on spermine to generate spermidine [7] . However, a more widespread peroxisomal enzyme, usually referred to as PAO, acts on the N 1 -acetyl derivatives of spermine and spermidine, forming spermidine and putrescine respectively [6, 8] . These acetylated polyamines are formed by the action of spermidine/spermine-N 1 -acetyltransferase (SSAT) and this enzyme appears to be the rate-limiting step in the reversal pathway, which may play a major role in maintaining polyamine homoeostasis [8] .
Although the polyamine biosynthetic enzymes are universally present in mammalian tissues, there are active uptake and efflux systems for polyamines. Polyamines (and agmatine, which can be converted into putrescine by agmatinase) are present in the diet and intestinal microflora so uptake provides an alternative supply. This may be insignificant under normal conditions. However, the up-regulation of this transport system in response to polyamine depletion may provide a major method of resistance to treatments limiting polyamine biosynthesis.
Antizyme (AZ) is a unique protein that regulates polyamine content (reviewed in [9, 10] ). AZ binds noncovalently to the ODC monomer. This binding inactivates ODC but, more importantly, targets it for degradation by the 26 S proteasome with release of free AZ, which can function again. The AZ mRNA contains an internal stop codon and a +1 frameshifting event is required for translation of the active protein. This frameshifting is increased by high levels of polyamines, which therefore inhibit their own synthesis by increasing AZ and reducing ODC. The polyamine transport system is also blocked by AZ through an unknown mechanism. It has also been suggested that AZ may stimulate polyamine excretion [11] . Therefore, AZ suppresses polyamine accumulation through multiple mechanisms. The rapid turnover of ODC requires a C-terminal domain that is not needed for activity. Deletion of this domain has therefore been used in some experiments to increase the steady-state level of ODC protein derived from transgenic constructs.
Mice with deletions of polyamine biosynthetic enzymes
Genetically altered mice or embryonic stem (ES) cells that have been described at present include gene deletions of ODC, AdoMetDC, spermine synthase and SSAT. Deletions of ODC [12] and AdoMetDC [13] are lethal at the earliest stages of embryonic development. A line of mice termed Gy contains a deletion of part of the X chromosome that includes the spermine synthase gene. These mice can only be propagated on the B6C3H background. Males lacking spermine synthase are sterile, have a wide variety of physical and neurological abnormalities and a very short life span (summarized in [14] ). Fibroblast cell lines from Gy mice [14] and ES cells with a targeted disruption of the spermine synthase gene [15] have been described and grow normally but differ in response to certain drugs. ES cells with gene deletions in SSAT (which is also located on the X chromosome) also grow normally and have normal polyamine content [16] but their responses to stresses that may alter polyamines have not been reported.
Rodents with increased polyamine metabolism in multiple tissues
Transgenic mice and rats in which ODC, AdoMetDC, spermidine synthase or SSAT has been increased generally in multiple tissues have been described (see [17] [18] [19] [20] [21] and references therein). In these studies, either a metallothionein promoter was used or the inserted transgene was a fragment of DNA containing the entire gene with its own associated promoter. This work has been described extensively and will be not be covered here. The general overproduction of ODC led to an increase in putrescine but had much less effect on higher polyamines. This is due partly to the limited AdoMetDC activity but mainly to the extensive homoeostatic control of polyamine metabolism, which can still occur via either post-translational mechanisms or regulatory influences mediated through the sequences in the inserted transgene. Mice overexpressing SSAT had a more striking phenotype with a substantial alteration in polyamine pools and a wide variety of changes including hair loss, female infertility, weight loss and altered lipid metabolism. The general nature of the alteration in polyamine metabolism, the presence of multiple secondary phenomena and the fact that these animals are maintained on a mixed genetic background makes them unsuitable for studies on carcinogenesis and tumour development.
Although it was reported that there was no increase in spontaneous tumours in mice overexpressing ODC by increasing the gene copy number [22] , a more recent study shows an increase in spontaneous tumour formation in mice overexpressing ODC from the mouse mammary tumour virus long-terminal-repeat promoter [23] .
Mice with altered cardiac polyamines
Transgenic mice have been generated in which either a C-terminally truncated ODC [24] or AdoMetDC [25] is expressed in the heart via the α-myosin heavy-chain promoter. These animals have a massive increase in enzymic activity but are viable. However, crosses in which both enzymes are expressed at this level are lethal in utero [25] . The increase in ODC (>1000-fold) leads to a slight cardiac hypertrophy but this is greatly increased upon treatment with isoproterenol and arginine, providing a useful model system to study the role of polyamines in hypertrophic growth. A constitutively active form of AZ (see below) has also been expressed from this promoter. In these animals the rise in ODC in response to isoproterenol is blocked but the cardiac hypertrophy induced by this drug is not diminished [26] .
Mice with increased ODC expression from the bovine keratin 5 (K5) or keratin 6 (K6) promoters
Bovine K5 and K6 promoter elements have been used to direct the expression of a C-terminally truncated ODC to specific skin cell populations. This led to a large increase in ODC activity with elevations in putrescine and spermidine. The mice exhibited hair loss, dermal follicular cysts, increased nail growth and skin wrinkling. In old mice, there was a high incidence of spontaneous squamous neoplasms with keratoacanthomas and well-differentiated papillomas [27] . Breeding of these mice to the C57BL/6J background abolished the development of spontaneous tumours but these mice were much more susceptible than controls to tumour development after treatment with an initiating dose of with 7,12-dimethylbenz(a)anthracene (DMBA) in adults or newborns. Furthermore, treatment with a tumour promoter such as PMA was not needed for tumour development [28, 29] . Treatment with α-difluoromethylornithine (DFMO), an ODC inhibitor, blocked the appearance of papillomas and caused a rapid regression of existing tumours in K6/ODC mice [30] .
Further evidence for the importance of ODC in the development of neoplastic growth was obtained by studies in which ODC expression was regulated by using a tetracyclineresponsive K6-driven construct. Down-regulation of the ODC expression by including doxycycline in the drinking water reduced papilloma incidence in response to DMBA [31] .
The sensitivity of K6/ODC mice to carcinogens is not limited to the polycyclic aromatic hydrocarbon DMBA. Several other carcinogens from different chemical classes were also shown to induce tumours in these mice within a short period, suggesting that they may be a useful model system for the rapid and sensitive identification of potential human carcinogens [32] . The use of chemical carcinogens to initiate tumorigenesis in K6/ODC mice is not absolutely required, as double transgenic mice combining the K6/ODC and v-Ha-ras transgenes rapidly develop spontaneous squamous tumours of the skin [33] . These tumours regress rapidly on treatment with DFMO [34] .
ODC also is implicated in photocarcinogenesis. K5/ODC mice developed a high incidence of papillomas and squamous cell carcinomas and a 100% incidence of pigmented cysts within 30 weeks of treatment with UVB radiation [35] . Shaved non-transgenic littermates and SKH1 mice (which are also hairless) did not develop any tumours or cysts until 50 weeks of treatment. DFMO prevented UVB-induced tumour development in K5/ODC mice [35] .
Transgenic ODC expression in K6/ODC mice leads to increased tumour incidence in response to DMBA in other strains including C3H/HeJ and FVB, although these were less sensitive than C57BL/6J. This may allow the identification of genes that influence skin tumour development whose expression or function is regulated by polyamines [36] . Notably, a high frequency of squamous cell carcinomas was seen in K6/ODC mice on the FVB background in these experiments.
Mice with increased AZ or dominantnegative ODC expression from the K5 or K6 promoters
The K5 and K6 promoters were also used to direct the expression of AZ to specific skin cell populations [37] . The AZ cDNA construct used had a single nucleotide deletion (T-205) to remove the requirement for polyamine-stimulated frameshifting in the translation of AZ mRNA. The cDNA contained both potential start codons although Western blots of epidermal extracts indicated that the second site was utilized preferentially in vivo. Both K5/AZ and K6/AZ transgenic mice developed normally and were phenotypically indistinguishable from wild-type littermates. The transgenic AZ expression blocked the increase in skin ODC induced by PMA and reduced epidermal and dermal polyamine content, particularly spermidine. In DMBA/PMA carcinogenesis studies on a mixed B6D2 genetic background, two founder lines of K6/AZ mice had a delay in tumour onset and a reduction in tumour multiplicity. K5/AZ mice also developed fewer papillomas than littermate controls and combination of these lines to produce K5/K6 double-transgenic animals yielded an additive decrease in tumour multiplicity [37] .
These transgenic lines were backcrossed on to the carcinogenesis-resistant C57BL/6J inbred strain as well as the sensitive DBA/2J strain and again subjected to a DMBA/PMA treatment protocol [38] . On the C57BL/6J background, tumour incidence and multiplicity were reduced in both K6/AZ lines. In K5/AZ transgenic mice, there was also a reduction in tumour multiplicity but the effect was smaller and there was no difference in tumour incidence. This result is consistent with the more complete inhibition of ODC activity in K6/AZ compared with K5/AZ mice in response to PMA application. On the DBA/2J background, both K5/AZ and K6/AZ developed fewer tumours with a slight delay in tumour onset.
The studies with ODC-and AZ-expressing mice show clearly that increased polyamine content plays a critical role in tumour development. A dominant-negative form of ODC was not effective in blocking carcinogenesis but did not fully lower endogenous ODC, which was stabilized due to the binding and sequestration of AZ by the stable dominant negative ODC, supporting the key physiological role of AZ in lowering polyamine levels [39] .
The hypothesis that ODC induction by pathways downstream of oncogenic ras is a necessary step in carcinogenesis was tested using a transgenic mouse line overexpressing a constitutively active mutant of mitogen-activated protein kinase/extracellular-signal-regulated protein kinase (ERK) kinase (MEK) in the skin under the control of the keratin 14 promoter (K14/MEK mice). Activation of the Raf/ERK pathway in these mice leads to moderate hyperplasia, with spontaneous skin tumour development within 5 weeks of birth. The tumours had high levels of ODC protein and activity, indicating that Raf/ERK activation is a sufficient stimulus for ODC induction. The K14/MEK mice on the ICR background were crossed with K5/AZ or K6/AZ mice on both the carcinogenesis-resistant C57BL/6J background and the sensitive DBA/2J background. Expression of AZ driven by either promoter significantly delayed tumour incidence and reduced tumour multiplicity on both backgrounds [40] . Since MEK overexpression causes hyperplasia and the K6 promoter requires hyperproliferation for maximal expression, K14/MEK-K6/AZ mice test whether ODC inhibition is effective in preventing tumour formation after a carcinogenic environment is established. The K5 promoter is constitutive, and K14/MEK-K5/AZ mice express AZ from birth in the same cells as the activated MEK protein.
These mice represent a model in which ODC is inhibited at the time of the initiating stimulus.
These results indicate that increased ODC activity is central to tumour development in response to overexpression of Ras activation pathways [40] . These conclusions are consistent with the response to DFMO. When K14/MEK mice were given DFMO in the drinking water from birth, there was a dramatic delay in the onset of tumour growth (approx. 6 weeks), and only 25% of DFMO-treated mice developed tumours by 15 weeks of age compared with 100% at 6 weeks in the untreated group.
AZ expression from the K5 promoter is not limited to the skin but may occur in other epithelial cells. The K5/AZ C57BL/6J mice were strikingly resistant to forestomach carcinogenesis by N-nitrosomethylbenzylamine (NMBA) [41] . Tumour formation in this model is increased by feeding a zinc-deficient diet, which induces forestomach epithelial cell proliferation. This proliferative response was blocked in K5/AZ mice and AZ was effective in reducing tumours in both zinc-sufficient and zinc-deficient mice. AZ expression reduced the proliferating cell nuclear antigen ('PCNA')-labelling index and the content of cyclin D1 and its catalytic partner Cdk4, key regulatory proteins controlling G 1 -to-S progression. AZ increased expression of Bax and increased the apoptopic index in the forestomach. These results demonstrate that overexpression of AZ stimulates apoptosis and restrains cell proliferation. Very similar changes were also produced in the NMBA/zinc-deficient mice by treatment with DFMO, confirming the importance of polyamines in carcinogenesis [41] .
In summary, the K5/AZ and K6/AZ mice demonstrate that AZ suppresses tumour growth in at least two animal cancer models and provide a valuable model system to evaluate the role of ODC and polyamines in tumorigenesis.
Mice with increased SSAT expression from the K6 promoter K6/SSAT mice appeared to be phenotypically normal and were indistinguishable from normal littermates. A preliminary experiment using hybrid B6D2 mice showed an increase in skin tumour incidence and multiplicity in response to a two-stage tumorigenesis protocol [42] . A more detailed study using K6/SSAT transgenic mice on the C57BL/6J background showed a 10-fold increase in the number of epidermal tumours that developed in response to a single application of DMBA followed by 19 weeks of promotion with PMA [43] . Tumours from transgenic animals showed marked elevations in SSAT enzyme activity and SSAT protein levels compared with tumours from nontransgenic littermates, and the accompanying changes in putrescine and N 1 -acetylspermidine pools indicated activation of SSAT-mediated polyamine catabolism in transgenic animals. Of particular interest was that an unusually high number of tumours rapidly progressed to carcinomas in the K6/SSAT mice. These findings are not due to the integration site of the SSAT transgene since they have now been confirmed using a second K6/SSAT transgenic line (C.S. Coleman, T.G. O'Brien and A.E. Pegg, unpublished work).
Although total polyamines were not reduced by the induction of the SSAT/PAO pathway, the relative content of polyamines was strikingly affected and the increases in putrescine and N 1 -acetylspermidine may indicate a key role for these polyamines in chemically induced mouse skin neoplasia. Another possibility is that the increased oxidative damage as a result of the elevated SSAT/PAO pathway is responsible for the advanced tumour phenotype. The extent to which high levels of SSAT may influence carcinogenesis in other tissues is not yet known.
Conclusions
Mouse models in which polyamine levels in particular cell types are perturbed by transgenic expression of proteins influencing polyamine metabolism are currently available and others could be developed. Modification of the cDNA for the expressed protein to avoid post-transcriptional regulation of the protein expression may be needed to maximize the alterations in polyamine content. These models provide opportunities for a greater understanding of the importance of polyamines in normal, hypertrophic and neoplastic growth and may in the future provide useful model systems to guide the optimal use of the polyamine pathway for the treatment and prevention of cancer. 
